^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Glioblastoma
    Drug:WP1122 (Viral replication inhibitor, Glycolysis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Moleculin Press Release
    Title:

    Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

    Published date:
    12/07/2022
    Excerpt:
    Moleculin Biotech, Inc...today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation of WP1122 for the treatment of Glioblastoma Multiforme (“GBM”).